Graft pre-treatment with fluticasone proprionate reduces graft-versus-host disease in allogenic hemtopoietic cell transplantation in mice

ABSTRACT: Hematopoietic cell transplantation (HCT) treats many blood conditions but remains underused due to complications such as graft-versus-host disease (GvHD). In GvHD, donor immune cells attack the patient, requiring powerful immunosuppressive drugs like glucocorticoids (GCs) to prevent death. In this study, we tested the hypothesis that donor cell pre-treatment with the glucocorticoid fluticasone propionate (FLU) prior to transplantation could increase hematopoietic stem cell (HSC) engraftment and reduce GvHD. Murine HSCs treated with FLU had increased HSC engraftment and reduced severity and incidence of GvHD after transplantation into allogeneic hosts. While most T cells died upon FLU treatment, donor T cells repopulated in the hosts and appeared less inflammatory and alloreactive. Regulato

SUBMITTER: Dr. Erika Varady 

PROVIDER: S-SCDT-10_15252-EMMM_202317748 | biostudies-other |

REPOSITORIES: biostudies-other